First-in-human phase 1 study of TAK-931, an oral cell division cycle 7 (CDC7) inhibitor, in patients (pts) with advanced solid tumors.

2506Background: TAK-931 is an oral selective inhibitor of CDC7, a protein kinase with key roles in DNA replication and DNA damage response. TAK-931 has demonstrated potent antitumor activity in var...